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Demographics Background
• Natural killer (NK) cells are lymphocytes belonging to the innate immune system which 
provide alloreactive graft versus leukemia (GVL) effect via germline encoded receptors 
including killer like immunoglobulin Receptors (KIR)
• NK cells can produce GVL in an HLA matched environment through KIR mediated interactions
• Effect of NK cell reconstitution kinetics on clinical outcomes in patients are not well studied
Selecting the Optimal Unrelated Hematopoietic Stem 
Cell Transplant Donor for Relapse Prevention in 
Acute Myeloid Leukemia
Objectives 
• Validate a score based on the net known KIR-KIRL interactions for a given donor-recipient pair
• Examine the effect component KIR-KIR Ligand (KIRL) interactions and KIR-KIRL scores have on 
HSCT outcomes
NK Cell Function 
• NK cells effector function is regulated by a balance of inhibitory and activating signals 
• KIR interact with HLA and HLA like molecules
• A large inhibitory signal leaves the NK cell anergic and the target cell is tolerated 
• A large activating signal leads to target cell death through interferon gamma, perforin 
and granzyme production 
Methods 
• Deidentified demographic and clinical outcomes data, as well as HLA and donor KIR 
genotyping information for this study were provided by the Center for International Blood and 
Marrow Transplant Research (CIBMTR, Milwaukee, WI)
• KIR component scores and the IM KIR Score were calculated as previously described and 
outlined in brief below
The Effect of In Vivo T Cell Depletion 
E. Krieger1, R. Qayyum1, and A. Toor1
• This large nationwide cohort validates our previous findings that the 
magnitude of iKIR and mKIR, as well as their combined IM KIR Score 
components are correlated with relapse risk after HCT for AML
• This challenges the notion that KIR are irrelevant to donor selection, and
raises the question that those donors with the highest IM KIR scores in an 
appropriate transplant setting, may be considered as optimal donors for 
HCT recipients with AML to allow for increased NK cell mediated 
alloreactivity. 
• Future clinical trials evaluating donor selection for URD HCT should include 
this measure to evaluate its value prospectively in uniformly treated 
patient cohorts
• Areas of further research 
• Extrapolating the HLA-KIR interaction scoring system to 
haploidentical and sibling transplant settings
• Functional assessment of KIR reconstitution after HSCT
• Quantification of NK cell IFN gamma production based on KIR-KIRL 
scores 
1. Virginia Commonwealth University, Richmond VA
Discussion
• 2365 DRPs transplanted for AML 
between 2010 and 2016 at 113 
centers across the United States 
for AML
• This cohort included adults aged 
20-83 years; 85% of DRPs were 
high-resolution 8/8 HLA-matched
• All patients received T cell replete 
grafts; 42% received in vivo T cell 
depletion 
• The majority received a graft of 
mobilized peripheral blood stem 
cells (PBSC), 86% and 59% received 
myeloablative conditioning.  
• During the 1,965,798 person-day 
follow up, 747 patients relapsed
and 1,175 patients died 
• A subset of 8/8 HLA matched grafts (n=1958) were next examined to remove the 
confounding effects of HLA mismatch on clinical outcomes.  
• Seven hundred and thirty  of these patients received ATG for in vivo T cell depletion
• Recipients who received ATG and IM=5 saw a 39% relapse reduction (SHR 0.61 95% CI 
0.46, 0.81, P=0.001)  
• Interaction analysis indicated DRPs with an IM=5 donor, when administered ATG, did not 
experience the increased relapse risk seen in IM<5 DRP who received ATG (interaction 
P=0.049)
𝐦𝐊𝐈𝐑 𝐂𝐨𝐦𝐩𝐨𝐧𝐞𝐧𝐭 𝐬𝐜𝐨𝐫𝐞 =|(𝑖𝐾𝐼𝑅 ∗ 𝑚𝐾𝐼𝑅𝐿) =−1 ∗ −1 = +1 = 1
𝐚𝐊𝐈𝐑 𝐂𝐨𝐦𝐩𝐨𝐧𝐞𝐧𝐭 𝐒𝐜𝐨𝐫𝐞 =|(𝑎𝐾𝐼𝑅 ∗ 𝑎𝐾𝐼𝑅𝐿) =+1 ∗ +1 = +1 = 1 𝐢𝐊𝐈𝐑 𝐂𝐨𝐦𝐩𝐨𝐧𝐞𝐧𝐭 𝐒𝐜𝐨𝐫𝐞 =|(𝑖𝐾𝐼𝑅 ∗ 𝑖𝐾𝐼𝑅𝐿) =−1 ∗ +1 = −1 = 1
Inhibitory	Missing	Ligand	(IM)	KIR-KIRL	Score	=	|iKIR|	+	|mKIR|	
Population frequencies of KIR-KIRL interaction scores for inhibitory KIR 
(iKIR), missing KIRL (mKIR), activating KIR (aKIR) and IM-KIR scores. 
KIR KIRL Component Scores
IM KIR Score  
• Higher iKIR and mKIR scores, 
were significantly associated 
with a reduced risk of AML 
relapse
• iKIR had a small impact on 
increasing the risk of cGVHD in 
unadjusted analysis, however 
this effect was not independent 
of the confounding variables 
included in the multivariate 
model
• As previously published aKIR
associated with their known 
HLA ligand did not effect 
outcomes 
Unadjusted and adjusted sub-distribution hazard and hazard ratios from competing risk and Cox 
proportional hazard models for the effect of iKIR, mKIR and aKIR on clinical outcomes 
Unadjusted and adjusted sub-distribution hazard and hazard ratios from competing risk and Cox 
proportional hazard models for the effect of IM KIR score of 5 vs IM KIR <5 on clinical outcomes 
• Given their independent predictive 
value for relapse following URD HCT, 
the cumulative effect of iKIR and 
mKIR component scores was then 
examined with the IM-KIR score
• An IM KIR score of 5 (IM=5) 
decreased relapse risk by 20% 
• Though this came at an increased risk 
of cGVHD and TRM; which most likely 
lead to lack of improvement of over 
all survival 
Unadjusted cumulative incidence curves by IM-KIR scores and in vivo T cell depletion with ATG depicting relapse.
